昆仑万维公告，预计2025年度净利润为负值，预计归属于上市公司股东的净利润区间为-19.5亿元 至-13.5亿元，上年同期为-15.95亿元；扣除非经常性损益后的净利润区间为-20.48亿元至-14.48亿元，上 年同期为-16.43亿元。业绩变动主要由于公司在市场推广和研发方面持续加大投入，以及收入同比增长 超过40%，海外收入占比进一步提升。 ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 （记者 曾健辉） 每经AI快讯，惠博普1月30日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润亏损1.5亿元 ~2亿元。基本每股收益亏损0.11元~0.15元。上年同期归属于上市公司股东的净利润亏损约1.91亿元。基 本每股收益亏损0.14元。业绩变动主要原因是，报告期内，受汇率波动影响，公司汇兑损失同比有所增 加，对净利润造成了一定负面影响；基于会计处理谨慎性原则，公司对墨西哥天然气发电项目仲裁事项 可能带来的额外损失进行了预提；对长期股权投资等资产存在的减值风险，计提了减值准备。 每日经济新闻 ...

Core Viewpoint - Huafang Co., Ltd. (600448.SH) is expected to report a significant net loss for the fiscal year 2025, with projected losses ranging from 230 million to 270 million yuan, indicating a downturn compared to the previous year [1] Financial Performance - The anticipated net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be between -228.7 million and -268.7 million yuan for 2025 [1] Reasons for Performance Decline - The primary reasons for the expected loss include: - Deterioration of the international trade environment, particularly the impact of tariff increases by certain countries, which has significantly affected the company's performance [1] - High inventory levels leading to a decrease in gross profit margin, necessitating impairment tests and the recognition of inventory write-downs [1] - Impact from national policies resulting in the shutdown of certain facilities at the company's self-owned power plant, leading to the recognition of fixed asset impairment provisions, with plans for a complete shutdown in the future [1]

格隆汇1月30日丨华泰股份(600308.SH)公布，公司2025年年度实现归属于母公司所有者的净利润预计 为-5000万元到-7000万元，与上年同期相比，将出现亏损。公司2025年年度归属于母公司所有者的扣除 非经常性损益的净利润预计为-1.25亿元到-1.45亿元。 2025年业绩波动相关说明：1. 2025年，受行业周期性调整及产品供需阶段性变化影响，公司部分产品销 售价格下降幅度大于成本下降幅度，毛利率有所下降，导致公司经营业绩出现一定波动。2. 公司70万吨 浆项目于2025年进入投产初期，产能爬坡与工艺磨合处于正常推进阶段，自产浆的规模效应与降本优势 尚未完全显现；同时，项目转固后相关折旧及财务支出计入当期损益，对短期利润形成阶段性影响。3. 为保障财务报表的审慎性，公司依据《企业会计准则》的相关规定，对部分应收款项、存货进行了减值 测试，并计提相应减值准备，该事项对本期业绩产生了一定影响。 ...

Core Viewpoint - The company anticipates a net profit loss attributable to shareholders of 2.1 billion to 2.7 billion yuan for 2025, a decrease from the previous year's loss of 2.977 billion yuan [1] Financial Performance - The expected net profit loss after deducting non-recurring items is projected to be between 2.25 billion and 2.85 billion yuan, compared to a loss of 4.05 billion yuan in the same period last year [1] - The basic earnings per share are expected to be a loss of 0.49 to 0.63 yuan per share, improving from a loss of 0.69 yuan per share in the previous year [1] Reasons for Performance - The anticipated performance decline is primarily due to the company's proactive adjustment of pricing strategies, leading to impairment signs in certain projects and the need to recognize impairment provisions [1] - The company expects a year-on-year reduction in net profit loss, mainly attributed to an increase in gross margin and investment income compared to the previous year [1]

Group 1 - The company Yashichuangneng (603378) has released a performance forecast indicating an expected net profit attributable to shareholders of the parent company for the year 2025 to be between -1.25 billion and -0.83 billion yuan [1] - The decline in operating revenue and gross margin is attributed to the ongoing weakness in the real estate and construction industries, along with a significant drop in orders [1]

Core Viewpoint - Ruichi Co., Ltd. forecasts a significant net loss for the year 2025, indicating a challenging financial outlook due to rising costs and declining profit margins [1] Financial Performance Summary - The company expects a net profit attributable to shareholders to be a loss between 46.54 million and 62.37 million yuan for 2025 [1] - The projected net profit, excluding non-recurring gains and losses, is anticipated to be a loss between 65.74 million and 81.57 million yuan [1] - The impact of non-recurring gains and losses on net profit is estimated to be approximately 19.20 million yuan, compared to 21.62 million yuan in the same period last year [1] Cost and Margin Analysis - The primary reasons for the significant change in operating performance include rising raw material prices and increased operating costs [1] - There has been an increase in expenses, leading to a decline in the overall gross profit margin [1]

实丰文化公告称，2025年公司预计亏损，归属于上市公司股东的净利润亏损1.5亿元 - 1.8亿元，较上年 同期盈利952.36万元下降1675.03% - 1990.04%；扣非后净利润亏损1.15亿元 - 1.45亿元，较上年同期亏 损3163.21万元下降263.55% - 358.40%。亏损主因包括参股公司经营亏损致投资损失、海外产品质量问 题赔偿、清理滞销产品及战略转型前期投入大等。 ...

Core Viewpoint - The company expects a significant net loss for the year 2025, with projections ranging from -130 million to -180 million yuan, an improvement from the previous year's loss of -300.838 million yuan [1] Financial Performance - The anticipated non-recurring net profit for 2025 is projected to be between -125 million and -175 million yuan, compared to -237.8685 million yuan in the same period last year [1] - The decline in profitability is attributed to intense competition in the telecommunications construction industry, a decrease in gross margins, compressed project profit margins, and a high proportion of bad debt provisions for accounts receivable [1] Regulatory Issues - Due to issues related to the internal control audit report, the company's stock will continue to be subject to additional risk warnings starting from July 4, 2025 [1]

Core Viewpoint - Saito Bio has announced a projected net loss for the year 2025, indicating significant financial challenges ahead due to various factors affecting its operations [1] Financial Performance - The company expects a net loss attributable to shareholders of between 63 million and 88 million yuan for the year 2025 [1] - The projected net loss, excluding non-recurring items, is anticipated to be between 66 million and 91 million yuan [1] Reasons for Performance Change - A decline in product market prices has led to a year-on-year decrease in overall gross margin, resulting in reduced gross profit [1] - As a high-tech biotechnology company focused on research and development, Saito Bio has increased its R&D expenditures, contributing to the decrease in net profit for the reporting period [1] - The company has recognized significant inventory impairment provisions for several intermediate products due to falling product prices, which has negatively impacted current profits [1]